Kähler K - Search Results

1

[Supportive therapy and management of side effects in dermato-oncology].

von Dücker L, Hüning S, Kähler K, Terheyden P, Nashan DRT. von Dücker L, et al. Among authors: kahler k. Hautarzt. 2019 Dec;70(12):975-988. doi: 10.1007/s00105-019-04496-z. Hautarzt. 2019. PMID: 31720719 German.

2

Current recommendations for prevention and therapy of extravasation reactions in dermato-oncology.

Kähler KC, Mustroph D, Hauschild A. Kähler KC, et al. J Dtsch Dermatol Ges. 2009 Jan;7(1):21-8. doi: 10.1111/j.1610-0387.2008.06752.x. Epub 2008 May 13. J Dtsch Dermatol Ges. 2009. PMID: 18479476 Review. English, German.

3

[Skin changes as a result of targeted therapies in oncology patients: cutaneous side effects of targeted therapies in oncology patients].

Kähler KC, Hauschild A. Kähler KC, et al. Hautarzt. 2009 May;60(5):433-40. doi: 10.1007/s00105-009-1754-9. Hautarzt. 2009. PMID: 19430753 Review. German.

4

[Current aspects of adjuvant therapy of malignant melanoma].

Kähler KC, Egberts F, Hauschild A. Kähler KC, et al. Hautarzt. 2010 Jun;61(6):523-31; quiz 532-3. doi: 10.1007/s00105-010-1964-1. Hautarzt. 2010. PMID: 20512304 Review. German.

5

[Adjuvant systemic treatment of melanoma].

Kähler KC, Egberts F, Hauschild A, Mohr P. Kähler KC, et al. Hautarzt. 2011 Jun;62(6):414, 416-22. doi: 10.1007/s00105-010-2040-6. Hautarzt. 2011. PMID: 21656113 Review. German.

6

Palliative treatment of skin metastases in dermato-oncology.

Kähler KC, Egberts F, Gutzmer R. Kähler KC, et al. J Dtsch Dermatol Ges. 2013 Nov;11(11):1041-5; quiz 1046. doi: 10.1111/ddg.12197. Epub 2013 Sep 9. J Dtsch Dermatol Ges. 2013. PMID: 24015966 Free article.

7

[Cutaneous side effects of anti-tumor therapy with BRAF and MEK inhibitors].

Gutzmer R, Hassel JC, Kähler KC, Loquai C, Mössner R, Ugurel S, Zimmer L, der das Ado FK. Gutzmer R, et al. Among authors: kahler kc. Hautarzt. 2014 Jul;65(7):582-9. doi: 10.1007/s00105-013-2733-8. Hautarzt. 2014. PMID: 24903029 German.

8

Actual practice of melanoma follow-up and treatment in Germany: results of a prospective, longitudinal cohort study.

Livingstone E, Eigentler TK, Windemuth-Kieselbach C, Hauschild A, Rompel R, Trefzer U, Nashan D, Kilian K, Debus D, Kähler KC, Mauerer A, Möllenhoff K, Dippel E, Schadendorf D. Livingstone E, et al. Among authors: kahler kc. Br J Dermatol. 2015 Jun;172(6):1646-1650. doi: 10.1111/bjd.13612. Epub 2015 Apr 29. Br J Dermatol. 2015. PMID: 25495472 No abstract available.

9

Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma.

Kähler KC, Hassel JC, Heinzerling L, Loquai C, Mössner R, Ugurel S, Zimmer L, Gutzmer R; “Cutaneous Side Effects” Committee of the Work Group Dermatological Oncology (ADO). Kähler KC, et al. J Dtsch Dermatol Ges. 2016 Jul;14(7):662-81. doi: 10.1111/ddg.13047. J Dtsch Dermatol Ges. 2016. PMID: 27373241

10

Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity.

Gutzmer R, Koop A, Meier F, Hassel JC, Terheyden P, Zimmer L, Heinzerling L, Ugurel S, Pföhler C, Gesierich A, Livingstone E, Satzger I, Kähler KC; German Dermatooncology Group (DeCOG). Gutzmer R, et al. Eur J Cancer. 2017 Apr;75:24-32. doi: 10.1016/j.ejca.2016.12.038. Epub 2017 Feb 16. Eur J Cancer. 2017. PMID: 28214654

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

191 results

Search Page